One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate JBT-101, a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body’s normal processes, to resolve innate immune responses without immunosuppression. The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit. Studies are also planned to evaluate tolerability and inflammation.
To Learn More Contact
Andrew Shaw at 516-562-2591
Latchmin Persaud at 516-562-3814.
ClinicalTrials.gov identifier: NCT03093402